Technical Analysis for FNCH - Finch Therapeutics Group, Inc.

Grade Last Price % Change Price Change
F 2.72 6.46% 0.17
FNCH closed up 6.46 percent on Monday, March 18, 2024, on 78 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Crossed Above 20 DMA Bullish 0.00%
New Uptrend Bullish 0.00%
Spinning Top Other 0.00%
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 6.46%
NR7 Range Contraction 6.46%

   Recent Intraday Alerts

Alert Time
Rose Above 50 DMA about 16 hours ago
10 DMA Support about 18 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Up 5% about 18 hours ago
20 DMA Support about 20 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Finch Therapeutics Group, Inc. Description

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Autoimmune Disease Infection Specialty Drugs Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Autism Spectrum Disorder Chronic Hepatitis B Virus Clostridioides Difficile Treatment Of Autism Spectrum Disorder University Of Minnesota

Is FNCH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.74
52 Week Low 2.1901
Average Volume 19,536
200-Day Moving Average 5.15
50-Day Moving Average 2.76
20-Day Moving Average 2.59
10-Day Moving Average 2.64
Average True Range 0.36
RSI (14) 51.46
ADX 26.57
+DI 37.87
-DI 11.51
Chandelier Exit (Long, 3 ATRs) 3.39
Chandelier Exit (Short, 3 ATRs) 3.26
Upper Bollinger Bands 3.02
Lower Bollinger Band 2.16
Percent B (%b) 0.65
BandWidth 33.31
MACD Line -0.02
MACD Signal Line -0.04
MACD Histogram 0.0216
Fundamentals Value
Market Cap 4.37 Million
Num Shares 1.61 Million
EPS -61.48
Price-to-Earnings (P/E) Ratio -0.04
Price-to-Sales 35.61
Price-to-Book 0.16
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.10
Resistance 3 (R3) 3.08 2.94 3.03
Resistance 2 (R2) 2.94 2.84 2.95 3.01
Resistance 1 (R1) 2.83 2.79 2.89 2.85 2.99
Pivot Point 2.69 2.69 2.72 2.70 2.69
Support 1 (S1) 2.58 2.59 2.64 2.60 2.45
Support 2 (S2) 2.44 2.54 2.45 2.43
Support 3 (S3) 2.33 2.44 2.41
Support 4 (S4) 2.35